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background:  Women have higher rates of ischemic and bleeding events than men following PCI performed after aspirin and clopidogrel 
loading. However, the differential risk of high platelet reactivity (HPR) in women vs. men is unknown.
methods:  We compared baseline characteristics and 2-year outcomes of 8,448 patients enrolled in the ADAPT-DES (Assessment of Dual 
Antiplatelet Therapy With Drug-Eluting Stents) study according to sex and HPR status (women with HPR=1118, 13.2%; women without 
HPR=1045, 12.4%; men with HPR=2491, 29.5%; men without HPR=3794, 44.9%). Multivariable associations between HPR and outcomes 
were assessed using Cox proportional hazards regression stratified by propensity score quintiles. 
results:  HPR was associated with a roughly doubled risk of stent thrombosis (ST) in both men and women (Figure LEFT) and with 
significantly reduced bleeding in women but not in men (Figure RIGHT). In propensity-adjusted multivariable models, HPR was an 
independent predictor of reduced bleeding only in women (women, HR 0.59, 95% CI, 0.44-0.80; men, HR 0.91, 95% CI, 0.75-1.11; P 
interaction 0.003) and of ST only in men; this association was attenuated among women (women, HR 1.86, 95% CI, 0.77-4.53; men, HR 
1.86, 95% CI, 1.08-3.2; P interaction 0.85).
Conclusion:  HPR has differential clinical impact on women versus men treated with clopidogrel. Although the associated risk of HPR for 
stent thrombosis was similar in both sexes, HPR was associated with reduced bleeding only among women.
 
